Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice.

Ebinger S, Zeller C, Carlet M, Senft D, Bagnoli JW, Liu WH, Rothenberg-Thurley M, Enard W, Metzeler KH, Herold T, Spiekermann K, Vick B, Jeremias I.

Haematologica. 2020 Feb 6. pii: haematol.2019.226282. doi: 10.3324/haematol.2019.226282. [Epub ahead of print] No abstract available.

2.

Self-resolving pulmonary artery pseudoaneurysm.

Lazic S, Rhodes A, Van Zeller C, Mahendran S.

BMJ Case Rep. 2019 Dec 5;12(12). pii: e232527. doi: 10.1136/bcr-2019-232527. No abstract available.

PMID:
31811096
3.

Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F; EMPEROR-Reduced Trial Committees and Investigators.

Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.

PMID:
31584231
4.

Alien limb phenomenon following posterior cerebral artery stroke: a distinct clinical entity.

Nowak DA, Engel A, Leutbecher M, Zeller C.

J Neurol. 2020 Jan;267(1):95-99. doi: 10.1007/s00415-019-09543-2. Epub 2019 Sep 27.

PMID:
31562560
5.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators.

Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.

PMID:
31523904
6.

Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.

Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, Lindenfeld J, Anker SD; EMPERIAL Investigators and National Coordinators.

Eur J Heart Fail. 2019 Jul;21(7):932-942. doi: 10.1002/ejhf.1486. Epub 2019 Jun 19.

7.

Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells.

Lima-Fernandes E, Murison A, da Silva Medina T, Wang Y, Ma A, Leung C, Luciani GM, Haynes J, Pollett A, Zeller C, Duan S, Kreso A, Barsyte-Lovejoy D, Wouters BG, Jin J, Carvalho DD, Lupien M, Arrowsmith CH, O'Brien CA.

Nat Commun. 2019 Mar 29;10(1):1436. doi: 10.1038/s41467-019-09309-4.

8.

Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC-Peptide Binding Data Set.

Bonsack M, Hoppe S, Winter J, Tichy D, Zeller C, Küpper MD, Schitter EC, Blatnik R, Riemer AB.

Cancer Immunol Res. 2019 May;7(5):719-736. doi: 10.1158/2326-6066.CIR-18-0584. Epub 2019 Mar 22. Erratum in: Cancer Immunol Res. 2019 Jul;7(7):1221.

PMID:
30902818
9.

A one-year cost-utility analysis of REBOA versus RTACC for non-compressible torso haemorrhage.

Renna MS, van Zeller C, Abu-Hijleh F, Tong C, Gambini J, Ma M.

Trauma. 2019 Jan;21(1):45-54. doi: 10.1177/1460408617738810. Epub 2017 Nov 24.

10.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
11.

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.

Januzzi J, Ferreira JP, Böhm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.

12.

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.

Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y.

J Diabetes Investig. 2019 Mar;10(2):418-428. doi: 10.1111/jdi.12910. Epub 2018 Sep 20.

13.

Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.

Neeland IJ, McGuire DK, Eliasson B, Ridderstråle M, Zeller C, Woerle HJ, Broedl UC, Johansen OE.

Diabetes Ther. 2018 Aug;9(4):1721. doi: 10.1007/s13300-018-0465-6.

14.

Does medical school lung function teaching need an update?

Renna MS, Van Zeller C.

Breathe (Sheff). 2018 Mar;14(1):e1-e3. doi: 10.1183/20734735.020117.

15.

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.

Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ.

Diabetes Care. 2018 Aug;41(8):1809-1816. doi: 10.2337/dc17-1525. Epub 2018 Jun 15.

PMID:
29907581
16.

Leading Dental Care Reform.

Zeller C.

J Am Dent Assoc. 2018 Jun;149(6):410-411. doi: 10.1016/j.adaj.2018.04.020. No abstract available.

PMID:
29804577
17.

Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.

Curry E, Zeller C, Masrour N, Patten DK, Gallon J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Bowtell DD, Brown R.

Cancer Res. 2018 Mar 15;78(6):1383-1391. doi: 10.1158/0008-5472.CAN-17-1650. Epub 2018 Jan 16.

18.

Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy").

Wunderli MD, Vonmoos M, Treichler L, Zeller C, Dziobek I, Kraemer T, Baumgartner MR, Seifritz E, Quednow BB.

Int J Neuropsychopharmacol. 2018 Apr 1;21(4):333-344. doi: 10.1093/ijnp/pyx098.

19.

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.

Kohler S, Zeller C, Iliev H, Kaspers S.

Adv Ther. 2017 Jul;34(7):1707-1726. doi: 10.1007/s12325-017-0573-0. Epub 2017 Jun 19.

20.

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.

Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE.

Hypertension. 2016 Dec;68(6):1355-1364. Epub 2016 Oct 10.

PMID:
27977392
21.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DMA, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A.

Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

22.

A Critical Evaluation of the PAXgene Tissue Fixation System:  Morphology, Immunohistochemistry, Molecular Biology, and Proteomics.

Mathieson W, Marcon N, Antunes L, Ashford DA, Betsou F, Frasquilho SG, Kofanova OA, McKay SC, Pericleous S, Smith C, Unger KM, Zeller C, Thomas GA.

Am J Clin Pathol. 2016 Jul;146(1):25-40. doi: 10.1093/ajcp/aqw023.

PMID:
27402607
23.

The incidence of implant fractures after knee arthroplasty.

Gilg MM, Zeller CW, Leitner L, Leithner A, Labek G, Sadoghi P.

Knee Surg Sports Traumatol Arthrosc. 2016 Oct;24(10):3272-3279. Epub 2016 May 6. Review.

PMID:
27154281
24.

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.

Neeland IJ, McGuire DK, Eliasson B, Ridderstråle M, Zeller C, Woerle HJ, Broedl UC, Johansen OE.

Diabetes Ther. 2015 Dec;6(4):635-642. Epub 2015 Nov 25. Erratum in: Diabetes Ther. 2018 Jun 21;:.

25.

The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P.

Fuchs R, Stracke A, Ebner N, Zeller CW, Raninger AM, Schittmayer M, Kueznik T, Absenger-Novak M, Birner-Gruenberger R.

Toxicology. 2015 Dec 2;338:17-29. doi: 10.1016/j.tox.2015.09.008. Epub 2015 Oct 9.

26.

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM trial investigators.

Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503. Epub 2015 Jul 14.

27.

Proof of concept for the use of macroinvertebrates as indicators of polychlorinated biphenyls (PCB) contamination in Lake Hartwell.

Lazorchak JM, Griffith MB, Mills M, Schubauer-Berigan J, McCormick F, Brenner R, Zeller C.

Environ Toxicol Chem. 2015 Jun;34(6):1277-82. doi: 10.1002/etc.2918. Epub 2015 May 7.

PMID:
25663426
28.

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators.

Diabetes Care. 2015 Mar;38(3):420-8. doi: 10.2337/dc14-1096. Epub 2014 Sep 30.

PMID:
25271206
29.

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators.

Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Erratum in: Lancet Diabetes Endocrinol. 2015 Sept;3(9):e7.

PMID:
24948511
30.

Differential effects of different vitamin D replacement strategies in patients with diabetes.

Alam U, Chan AW, Buazon A, Van Zeller C, Berry JL, Jugdey RS, Asghar O, Cruickshank JK, Petropoulos IN, Malik RA.

J Diabetes Complications. 2014 Jan-Feb;28(1):66-70. doi: 10.1016/j.jdiacomp.2013.09.003. Epub 2013 Oct 16.

PMID:
24139562
31.

Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors.

Sriraksa R, Zeller C, Dai W, Siddiq A, Walley AJ, Limpaiboon T, Brown R.

Cancer Prev Res (Phila). 2013 Dec;6(12):1348-55. doi: 10.1158/1940-6207.CAPR-13-0104. Epub 2013 Oct 2.

32.

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators.

Cardiovasc Diabetol. 2013 Sep 5;12:129. doi: 10.1186/1475-2840-12-129.

33.

Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.

Dai W, Zeller C, Masrour N, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2013 Oct 15;19(20):5788-5797. doi: 10.1158/1078-0432.CCR-13-1217. Epub 2013 Aug 21.

34.

The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles.

Zeller C, Dai W, Curry E, Siddiq A, Walley A, Masrour N, Kitsou-Mylona I, Anderson G, Ghaem-Maghami S, Brown R, El-Bahrawy M.

Am J Pathol. 2013 Mar;182(3):668-77. doi: 10.1016/j.ajpath.2012.11.040. Epub 2013 Jan 25.

35.

Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.

Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S, Brown R.

Oncogene. 2013 Sep 19;32(38):4586-92. doi: 10.1038/onc.2012.477. Epub 2012 Nov 5.

PMID:
23128397
36.

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R.

Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.

37.

Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.

Zeller C, Brown R.

Ther Adv Med Oncol. 2010 Sep;2(5):319-29. doi: 10.1177/1758834010375759.

38.

Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.

Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.

39.

CpG-island methylation study of liver fluke-related cholangiocarcinoma.

Sriraksa R, Zeller C, El-Bahrawy MA, Dai W, Daduang J, Jearanaikoon P, Chau-In S, Brown R, Limpaiboon T.

Br J Cancer. 2011 Apr 12;104(8):1313-8. doi: 10.1038/bjc.2011.102. Epub 2011 Mar 29.

40.

Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes.

Courneya JP, Luzina IG, Zeller CB, Rasmussen JF, Bocharov A, Schon LC, Atamas SP.

Fibrogenesis Tissue Repair. 2010 Jun 10;3:9. doi: 10.1186/1755-1536-3-9.

41.

Role of tumor necrosis factor receptor 1 in sex differences of stem cell mediated cardioprotection.

Zeller CN, Wang Y, Markel TA, Weil B, Abarbanell A, Herrmann JL, Kelly ML, Coffey A, Meldrum DR.

Ann Thorac Surg. 2009 Mar;87(3):812-9. doi: 10.1016/j.athoracsur.2008.12.033.

PMID:
19231395
42.

A Bayesian network view on nested effects models.

Zeller C, Fröhlich H, Tresch A.

EURASIP J Bioinform Syst Biol. 2009:195272. doi: 10.1155/2009/195272. Epub 2009 Jan 8.

43.

Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands.

Dai W, Teodoridis JM, Graham J, Zeller C, Huang TH, Yan P, Vass JK, Brown R, Paul J.

BMC Bioinformatics. 2008 Aug 8;9:337. doi: 10.1186/1471-2105-9-337.

44.

Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Zeller CB, Appenzeller S.

Curr Cardiol Rev. 2008 May;4(2):116-22. doi: 10.2174/157340308784245775.

45.

Postnatal lung function in the developing rat.

Bolle I, Eder G, Takenaka S, Ganguly K, Karrasch S, Zeller C, Neuner M, Kreyling WG, Tsuda A, Schulz H.

J Appl Physiol (1985). 2008 Apr;104(4):1167-76. doi: 10.1152/japplphysiol.00587.2007. Epub 2008 Jan 10.

46.

Illuminating Gbeta5 signaling.

Zeller CE, Dohlman HG.

Mol Pharmacol. 2007 Oct;72(4):810-1. Epub 2007 Jul 16.

PMID:
17636044
47.

The RACK1 ortholog Asc1 functions as a G-protein beta subunit coupled to glucose responsiveness in yeast.

Zeller CE, Parnell SC, Dohlman HG.

J Biol Chem. 2007 Aug 24;282(34):25168-76. Epub 2007 Jun 25.

48.

Deep rolling of titanium rods for application in modular total hip arthroplasty.

Schuh A, Zeller C, Holzwarth U, Kachler W, Wilcke G, Zeiler G, Eigenmann B, Bigoney J.

J Biomed Mater Res B Appl Biomater. 2007 May;81(2):330-5.

PMID:
16969829
49.

Panel discussion: remedy effectiveness: what works, what doesn't?

Zeller C, Cushing B.

Integr Environ Assess Manag. 2006 Jan;2(1):75-9.

PMID:
16640321
50.

Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis.

Appenzeller S, Zeller CB, Annichino-Bizzachi JM, Costallat LT, Deus-Silva L, Voetsch B, Faria AV, Zanardi VA, Damasceno BP, Cendes F.

Clin Neurol Neurosurg. 2005 Aug;107(5):371-8. Epub 2004 Nov 18.

PMID:
16023530

Supplemental Content

Loading ...
Support Center